Core Viewpoint - China Traditional Chinese Medicine announced that it expects to report a net loss of approximately 350 million to 500 million yuan in 2025, a significant decline from a net profit of about 20.77 million yuan in the same period last year [1] Financial Performance - The adjusted net profit is projected to decrease by 45% to 55% year-on-year, compared to approximately 636 million yuan in the previous year [1] - The primary reasons for the loss include a decline in revenue and profitability from the Chinese medicine formula granule business [1] Impairments and Adjustments - The company anticipates an increase in goodwill impairment, intangible asset impairment, and credit impairment during this period [1] - The board stated that these matters will not adversely affect the company's ongoing operational capability [1] Reporting and Future Guidance - The adjusted net profit mentioned is not defined under Hong Kong Financial Reporting Standards [1] - Shareholders and potential investors are advised that the information in the announcement is a preliminary assessment, with the final performance report expected to be released by the end of March 2026 [1]
中国中药：2025年亏损净额预估约为3.5亿元至5亿元